Avea, a revolutionary company creating science-driven solutions for a longer and healthier life, is celebrating after successfully securing an impressive $5 million in seed funding. The latest funding round, led by Maximon, their primary investor, raised an extra $2.5 million, which will fuel Avea's growth in Europe and help establish a solid footing in the Asia-Pacific (APAC) region.
Hot on the heels of launching six transformative products, Avea has carved out a leading position in Europe's longevity science market. The newly acquired funds will serve various strategic purposes, including enhancing production, boosting sales and marketing, strengthening European distribution networks, and paving the way for pioneering human studies. Importantly, a substantial part of the investment will help Avea tap into the expanding Asian market for longevity science products.
Since its recent launch, Avea's product lineup, powered by longevity science, has drawn significant acclaim and consumer demand. Their standout product, the Collagen Activator, was developed in collaboration with scientists from the prestigious ETH in Zurich, Switzerland. This product has shown incredible promise, boosting the body's collagen production up to four times more effectively than regular collagen supplements. Still awaiting patent approval, the Collagen Activator is already bringing remarkable results for Avea's customers, cementing Avea's reputation as a trusted brand in the industry.
Looking ahead, Avea is excited about the prospects of expanding into the APAC market. "Our well-established reputation in Europe, coupled with the exceptional performance of our products, particularly the Collagen Activator, give us confidence that Avea's longevity science solutions will resonate with APAC consumers," shared Dr. Tobias Reichmut, Founding Partner at Maximon.
